Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

1.

Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells.

Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM.

PLoS One. 2013;8(1):e54595. doi: 10.1371/journal.pone.0054595. Epub 2013 Jan 23.

PMID:
23355882
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.

Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Epub 2012 Sep 25. Erratum in: Cancer Sci. 2013 Oct;104(10):1389.

PMID:
22909393
[PubMed - indexed for MEDLINE]
3.

Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.

Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z, Hai C.

Carcinogenesis. 2013 Jun;34(6):1323-30. doi: 10.1093/carcin/bgt058. Epub 2013 Feb 12.

PMID:
23404993
[PubMed - indexed for MEDLINE]
Free Article
4.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
[PubMed - indexed for MEDLINE]
5.

HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.

Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.

Cancer Lett. 2012 Mar 28;316(2):187-95. doi: 10.1016/j.canlet.2011.10.037. Epub 2011 Nov 4.

PMID:
22182943
[PubMed - indexed for MEDLINE]
6.

IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.

Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, Hong S, Hong SS.

Cancer Lett. 2013 Feb 1;329(1):99-108. doi: 10.1016/j.canlet.2012.10.028. Epub 2012 Nov 8.

PMID:
23142281
[PubMed - indexed for MEDLINE]
7.

Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.

Carcinogenesis. 2013 Jun;34(6):1331-42. doi: 10.1093/carcin/bgt060. Epub 2013 Feb 7.

PMID:
23393227
[PubMed - indexed for MEDLINE]
Free Article
8.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

PMID:
23167739
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro.

Li M, Li Q, Zhang YH, Tian ZY, Ma HX, Zhao J, Xie SQ, Wang CJ.

Anticancer Drugs. 2013 Jan;24(1):32-42. doi: 10.1097/CAD.0b013e328359affd.

PMID:
23032518
[PubMed - indexed for MEDLINE]
10.

Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.

Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.

Cancer Lett. 2010 Jan 28;287(2):196-206. doi: 10.1016/j.canlet.2009.06.011. Epub 2009 Jul 17.

PMID:
19616371
[PubMed - indexed for MEDLINE]
11.

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.

Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25. doi: 10.1007/s00280-013-2139-4. Epub 2013 Apr 2.

PMID:
23546591
[PubMed - indexed for MEDLINE]
12.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

PMID:
20860815
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.

Cancer Res. 2008 Aug 15;68(16):6698-707. doi: 10.1158/0008-5472.CAN-08-0257.

PMID:
18701494
[PubMed - indexed for MEDLINE]
Free Article
14.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway.

Xiong Y, Lu QJ, Zhao J, Wu GY.

Asian Pac J Cancer Prev. 2012;13(7):3275-9.

PMID:
22994747
[PubMed - indexed for MEDLINE]
Free Article
16.

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.

Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D, Pan S, Liu J, Jiang H, Liu L.

Mol Cancer. 2013 Oct 5;12(1):114. doi: 10.1186/1476-4598-12-114.

PMID:
24093956
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B.

Gastroenterology. 2012 Sep;143(3):811-20.e1-15. doi: 10.1053/j.gastro.2012.05.033. Epub 2012 May 26.

PMID:
22641068
[PubMed - indexed for MEDLINE]
18.

Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.

Zhang DM, Liu JS, Tang MK, Yiu A, Cao HH, Jiang L, Chan JY, Tian HY, Fung KP, Ye WC.

Eur J Pharmacol. 2012 Oct 5;692(1-3):19-28. doi: 10.1016/j.ejphar.2012.06.045. Epub 2012 Jul 25.

PMID:
22841670
[PubMed - indexed for MEDLINE]
19.

MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.

Wilson JM, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M.

J Surg Res. 2014 Oct;191(2):280-5. doi: 10.1016/j.jss.2014.05.083. Epub 2014 Jun 4.

PMID:
24996256
[PubMed - indexed for MEDLINE]
20.

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.

Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C.

J Hepatol. 2012 Jan;56(1):176-83. doi: 10.1016/j.jhep.2011.07.013. Epub 2011 Aug 9.

PMID:
21835141
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk